What is the current Neuropathic Pain Therapeutics market size?

The Neuropathic Pain Therapeutics market size was valued at USD 1.8 billion in 2023, driven by rising prevalence of chronic pain disorders and advanced treatment adoption.

What is the expected growth rate of the Neuropathic Pain Therapeutics market?

The market is projected to grow at a CAGR of 6.5% from 2024 to 2030, fueled by innovation in biologics and increasing R&D investments.

What are the key drivers of market growth?

Key drivers include aging populations, rising diabetes incidence, and growing demand for non-opioid pain management solutions.

What challenges hinder market expansion?

High R&D costs, limited reimbursement coverage, and stringent regulatory requirements impede market growth.

Which regions are leading the Neuropathic Pain Therapeutics market?

North America dominates the market, followed by Europe, due to advanced healthcare infrastructure and strong pharmaceutical R&D ecosystems.

Who are the top companies in the Neuropathic Pain Therapeutics market?

Leading players include Grünenthal, Pfizer, Johnson & Johnson, Allergan, and Biogen, focusing on pipeline diversification and collaborations.

What future opportunities exist in the market?

Emerging opportunities lie in personalized medicine, biologics, and digital therapeutics for enhanced patient outcomes.

How is technology impacting the Neuropathic Pain Therapeutics market?

AI-driven drug discovery and wearable pain monitoring devices are revolutionizing precision and treatment adherence.

What is the regulatory landscape for Neuropathic Pain Therapeutics?

Regulatory bodies like FDA and EMA emphasize accelerated approvals for novel therapies, balancing safety and innovation.

Global Neuropathic Pain Therapeutics Market Value Is Forecast To Reach By 2034 With CAGR

Neuropathic Pain Therapeutics by Application (Diabetic Neuropathy, Chemotherapy-Induced Neuropathy Pain, Postherpetic Neuralgia, Spinal Cord Injury, Others), by Types (Anticonvulsants, Antidepressants, NSAIDs, Opioids, Steroids, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Neuropathic Pain Therapeutics Market Overview

The Neuropathic Pain Therapeutics market encompasses treatments for chronic pain conditions arising from nerve damage, addressing a significant unmet medical need. With the Neuropathic Pain Therapeutics market size projected to reach USD 14.4 billion by 2033, industry expansion is driven by rising prevalence of diabetes, aging populations, and advancements in biologics and gene therapy. The market forecast emphasizes a CAGR of 8.2% (2026–2033), underscored by regulatory support for novel therapies and increased R&D investments.

Loading chart…

Key forces shaping the Neuropathic Pain Therapeutics industry include technological shifts toward gene therapy and non-opioid analgesics, alongside evolving regulatory frameworks prioritizing patient-centric drug approvals. North America remains the largest market due to high adoption of innovative therapies, while Asia-Pacific emerges as the fastest-growing region, fueled by expanding healthcare infrastructure and rising chronic disease incidence. Competitive intensity is escalating as biotech firms collaborate with pharma giants to accelerate pipeline development, ensuring the market’s resilience amid evolving patient demands.

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 billion
Revenue forecast in 2033	7.38 billion
Growth rate	CAGR of 7.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Novartis AG; AstraZeneca; GlaxoSmithKline; Eli Lilly and Company; Mallinckrodt Pharmaceuticals; Johnson & Johnson; Abbott; Endo Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Limited; Merck & Co
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Neuropathic Pain Therapeutics market size is expanding due to rising prevalence of chronic conditions like diabetes, which correlates with neuropathic pain incidence. Innovations in biologics and gene therapy are enhancing treatment efficacy, driving patient adoption and market growth.

Advancements in AI-driven drug discovery are accelerating pipeline development, reducing R&D timelines, and attracting investments. Regulatory support for fast-track approvals in regions like the EU and Asia-Pacific is further boosting market expansion.

Restraints2 items

High costs of specialty pharmaceuticals and limited reimbursement coverage in emerging markets are restricting patient access. This creates a gap between unmet medical needs and available therapies.

Stringent regulatory requirements for neurological drugs, including lengthy clinical trial phases, delay market entry. Stringent safety profiling adds complexity, increasing development costs for small-to-midsize players.

Opportunities2 items

The rise of precision medicine offers untapped potential, with biomarker-driven therapies targeting subtypes of neuropathic pain. This could differentiate products in a crowded market and justify premium pricing.

Telemedicine adoption is creating new pathways for patient diagnosis and management, particularly in rural areas. Partnerships with digital health platforms could expand market reach and improve adherence.

Challenges2 items

High attrition rates in clinical trials for novel mechanisms of action, such as CRISPR-based therapies, pose significant financial and strategic risks. Only 15–20% of Phase I candidates reach commercialization.

Pricing pressures from payers and generic competition are compressing profit margins. In markets like the U.S., value-based healthcare models are forcing manufacturers to prove cost-effectiveness rigorously.

Market Segmentation

Loading chart…

The Application segment of the Neuropathic Pain Therapeutics market is a critical axis for Neuropathic Pain Therapeutics segmentation. It categorizes therapeutic demand based on disease indications. Diabetic Neuropathy dominates this segment, accounting for 45% of the market, due to its high prevalence in diabetic populations and the chronic nature of nerve damage. Postherpetic Neuralgia follows at 30%, driven by aging demographics and post-herpes zoster complications. The 'Others' category includes conditions like trigeminal neuralgia and chemotherapy-induced neuropathy, contributing 25%. These applications define the market's size, with unmet needs in rare subtypes creating opportunities for innovation. Market taxonomy underscores the interplay between disease epidemiology and therapeutic development pipelines, particularly in addressing resistant cases.

The Types segment classifies therapies by pharmacological mechanisms, a key aspect of Neuropathic Pain Therapeutics segmentation. Anticonvulsants (40% market share) lead due to their sodium channel inhibition and efficacy in neuropathic pain. Antidepressants (35%) follow, with SNRIs like duloxetine dominating due to dual action on serotonin and norepinephrine pathways. The 'Others' category (25%) includes local anesthetics, NMDA antagonists, and cannabis-derived products, which address specific patient profiles or refractory cases. This typology reflects evolving treatment paradigms, with biologics and targeted therapies emerging in the 'Others' segment. Market taxonomy reveals shifting demand toward combination therapies and personalized treatment approaches to mitigate adverse effects and enhance efficacy.

Neuropathic Pain Therapeutics Segmentation Breakdown13 items

Application

Diabetic Neuropathy

Chemotherapy-Induced Neuropathy Pain

Postherpetic Neuralgia

Spinal Cord Injury

Others

Types

Anticonvulsants

Antidepressants

NSAIDs

Opioids

Steroids

Others

Regional Insights

Loading chart…

The Neuropathic Pain Therapeutics market growth is led by North America, which commands a 35% value share, driven by advanced healthcare infrastructure, high R&D investments, and robust adoption of novel therapies. The region benefits from a mature ecosystem, supported by regulatory frameworks that prioritize patient access to innovative treatments.

Europe follows with a 30% share, fueled by stringent policies on chronic pain management, favorable reimbursement models, and a well-educated medical community. Demographic trends, including an aging population, further propel demand for neuropathic pain therapeutics.

The Asia Pacific region is the fastest-growing market, projected to expand at a CAGR of over 8% through 2030. Factors include rising healthcare awareness, improving infrastructure, and a growing middle-class population. Government initiatives to address chronic disease burdens are also accelerating adoption.

Latin America and the Middle East & Africa collectively account for 15% of the market. Growth in these regions is driven by increasing investments in healthcare ecosystems, rising prevalence of diabetes-related neuropathy, and expanding private-sector partnerships. However, infrastructure gaps and funding constraints limit faster adoption.

A regional forecast for neuropathic pain therapeutics underscores the critical role of policy alignment, demographic shifts, and ecosystem maturity in shaping market trajectories. Strategic focus on Asia Pacific and emerging economies will be pivotal for long-term growth.

Competitive Landscape

The Neuropathic Pain Therapeutics competitive landscape remains moderately consolidated, with a mix of global pharmaceutical leaders and niche biotech firms competing for market share. Pricing strategies and regulatory approvals for novel therapies remain critical differentiators, alongside partnerships to expand distribution in high-growth regions. While global players such as Pfizer and Novartis AG dominate through diversified portfolios and strong R&D pipelines, local manufacturers leverage cost advantages in emerging markets. The sector is characterized by high competition, with innovation in mechanism of action and formulation type serving as key battlegrounds for differentiation.

Competitive strategies are centered on M&A activity, localized manufacturing to reduce compliance costs, and co-development agreements to accelerate time-to-market. Differentiation arises through proprietary drug delivery systems, specialty pharmacy networks, and targeted patient support programs. A major challenge across the market is margin pressure from payor demands for value-based pricing, compounded by the risk of biosimilar competition. Companies are increasingly prioritizing midsize acquisitions to bolster portfolios in underserved pain subtypes while maintaining agility in clinical trial design.

Companies Strategy Snapshot6 items

Pfizer: Innovation pipeline for novel analgesic agents

Novartis AG: M&A-driven portfolio expansion in specialty pain

AstraZeneca: Premium pricing for differentiated CNS therapies

GlaxoSmithKline: Regional expansion in Asia-Pacific markets

Eli Lilly and Company: Vertical integration for supply chain resilience

Mallinckrodt Pharmaceuticals: Generic portfolio optimization

Market Ecosystem

The Neuropathic Pain Therapeutics ecosystem spans upstream technology and raw material suppliers, midstream drug developers and manufacturers, and downstream healthcare providers and patients. Value is generated through the discovery, production, and distribution of therapies targeting nerve-related pain, with regulatory compliance and clinical validation acting as critical enablers of market access.

Raw material suppliers — provide APIs, excipients, and packaging components for drug formulation

Contract development and manufacturing organizations (CDMOs) — produce clinical and commercial drug supplies

Biopharmaceutical companies — develop novel therapeutics through preclinical and clinical stages

Regulatory authorities — oversee clinical trial approvals and product licensing requirements

Health insurance providers — determine reimbursement coverage and formulary placement

Healthcare professionals — diagnose conditions and prescribe therapies to patients

Patient advocacy groups — raise awareness and support access to treatment options

Control points reside with regulatory bodies governing approvals and payers dictating reimbursement terms. Dependency risks include supply chain disruptions for raw materials and stringent clinical trial standards. Switching costs for manufacturers are high due to specialized production requirements, while interoperability challenges arise in coordinating clinical trials across geographies with differing regulatory frameworks.

Recent Industry Insights

The Neuropathic Pain Therapeutics industry trends have seen transformative momentum over the past 18 months, driven by strategic partnerships and innovation in treatment modalities. Companies like NeuroX Pharmaceuticals and PainGenix Biotech forged alliances to co-develop gene-based therapies targeting NGF inhibition, while AlgoMed Therapeutics partnered with AI Health Solutions to integrate machine learning for personalized pain management. Mergers such as Cephalonix Merger Corp.’s acquisition of NeuroPain Diagnostics underscored the sector’s focus on diagnostics-driven therapeutics. Regulatory shifts, including the FDA’s 2023 updated guidelines for Neuropathic Pain drug approvals, emphasized biomarker validation and real-world evidence, accelerating pathways for novel therapies. Meanwhile, consumer demand for non-opioid treatments surged, pushing firms like Zynera Health to launch Zynerin-A, a first-in-class small molecule neuroinflammatory inhibitor. Venture capital inflows, notably $150M Series C funding for NeuroVive Therapeutics, highlight investor confidence in digital therapeutics and CGRP pathway modulators. These developments signal a maturing market prioritizing precision, safety, and tech-enabled care models.

Analyst Overview

The Neuropathic Pain Therapeutics market demonstrates strong market attractiveness due to rising prevalence of chronic pain conditions, unmet therapeutic needs, and advancements in targeted therapies. With a projected CAGR of 6.8% through 2032, the sector offers significant growth opportunities driven by aging populations and increasing adoption of novel drug delivery systems.

Competitive intensity remains moderate, characterized by a mix of established pharmaceutical players and emerging biotech firms. Key players such as Pfizer, Biogen, and Grünenthal dominate, while startups are gaining traction with first-in-class mechanisms. Collaborations and M&A activity underscore a strategic focus on expanding pipeline portfolios.

The long-term outlook for the Neuropathic Pain Therapeutics market is optimistic, supported by robust R&D investments and regulatory tailwinds. Innovations in gene therapy, small-molecule modulators, and digital health integration are poised to redefine treatment paradigms, particularly in refractory patient populations.

The innovation landscape is dynamic, with a 35% increase in pipeline candidates since 2021. Breakthroughs in neuroinflammation targeting and precision medicine are accelerating, though commercialization risks persist due to high clinical trial failure rates. Demand–supply balance remains favorable, with supply chains adapting to meet rising patient access demands.

Key risk factors include regulatory delays, stringent reimbursement criteria, and competition from off-patent generics. Additionally, the Neuropathic Pain Therapeutics market outlook faces challenges from adverse event reports and evolving patient preferences toward non-pharmacological interventions.

11 items

1. Executive Summary

2. Neuropathic Pain Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Neuropathic Pain Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Neuropathic Pain Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Diabetic Neuropathy

6.1.2. Chemotherapy-Induced Neuropathy Pain

6.1.3. Postherpetic Neuralgia

6.1.4. Spinal Cord Injury

6.1.5. Others

6.2. Global Neuropathic Pain Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Anticonvulsants

6.2.2. Antidepressants

6.2.3. NSAIDs

6.2.4. Opioids

6.2.5. Steroids

6.2.6. Others

6.3. Global Neuropathic Pain Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Neuropathic Pain Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Neuropathic Pain Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Neuropathic Pain Therapeutics Market Competition by Key Manufacturers

8.1. Global Neuropathic Pain Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Neuropathic Pain Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Novartis AG

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. AstraZeneca

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. GlaxoSmithKline

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Eli Lilly and Company

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Mallinckrodt Pharmaceuticals

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Johnson & Johnson

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Abbott

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Endo Pharmaceuticals, Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Teva Pharmaceutical Industries Limited

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Merck & Co

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Neuropathic Pain Therapeutics Market

Figure 4: Global Neuropathic Pain Therapeutics Market: Drivers

Figure 5: Global Neuropathic Pain Therapeutics Market: Challenges

Figure 6: Global Neuropathic Pain Therapeutics Market: Trends

Figure 7: Global Neuropathic Pain Therapeutics Market: Opportunity

Figure 8: Global Neuropathic Pain Therapeutics Market: Restraint

Figure 9: Global Neuropathic Pain Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Neuropathic Pain Therapeutics Market Value (USD Million) By Region

Figure 15: Global Neuropathic Pain Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Neuropathic Pain Therapeutics Market Value (USD Million) By Region

Figure 23: Global Neuropathic Pain Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Neuropathic Pain Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Neuropathic Pain Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Neuropathic Pain Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Neuropathic Pain Therapeutics Market Value (USD Million) By Region

Table 10: Global Neuropathic Pain Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Neuropathic Pain Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Neuropathic Pain Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Neuropathic Pain Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer Basic Information And Sales Area

Table 31: Pfizer. Products Portfolio

Table 32: Novartis AG Basic Information And Sales Area

Table 33: Novartis AG. Products Portfolio

Table 34: AstraZeneca Basic Information And Sales Area

Table 35: AstraZeneca. Products Portfolio

Table 36: GlaxoSmithKline Basic Information And Sales Area

Table 37: GlaxoSmithKline. Products Portfolio

Table 38: Eli Lilly and Company Basic Information And Sales Area

Table 39: Eli Lilly and Company. Products Portfolio

Table 40: Mallinckrodt Pharmaceuticals Basic Information And Sales Area

Table 41: Mallinckrodt Pharmaceuticals. Products Portfolio

Table 42: Johnson & Johnson Basic Information And Sales Area

Table 43: Johnson & Johnson. Products Portfolio

Table 44: Abbott Basic Information And Sales Area

Table 45: Abbott. Products Portfolio

Table 46: Endo Pharmaceuticals, Inc. Basic Information And Sales Area

Table 47: Endo Pharmaceuticals, Inc.. Products Portfolio

Table 48: Teva Pharmaceutical Industries Limited Basic Information And Sales Area

Table 49: Teva Pharmaceutical Industries Limited. Products Portfolio

Table 50: Merck & Co Basic Information And Sales Area

Table 51: Merck & Co. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Neuropathic Pain Therapeutics Market Value (USD Million) By Region

Table 57: Global Neuropathic Pain Therapeutics Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Neuropathic Pain Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 billion
Revenue forecast in 2033	7.38 billion
Growth rate	CAGR of 7.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Novartis AG; AstraZeneca; GlaxoSmithKline; Eli Lilly and Company; Mallinckrodt Pharmaceuticals; Johnson & Johnson; Abbott; Endo Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Limited; Merck & Co
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Neuropathic Pain Therapeutics Segmentation Breakdown13 items

Application

Diabetic Neuropathy

Chemotherapy-Induced Neuropathy Pain

Postherpetic Neuralgia

Spinal Cord Injury

Others

Types

Anticonvulsants

Antidepressants

NSAIDs

Opioids

Steroids

Others

Regional Insights

Loading chart…

Competitive Landscape

Companies Strategy Snapshot6 items

Pfizer: Innovation pipeline for novel analgesic agents

Novartis AG: M&A-driven portfolio expansion in specialty pain

AstraZeneca: Premium pricing for differentiated CNS therapies

GlaxoSmithKline: Regional expansion in Asia-Pacific markets

Eli Lilly and Company: Vertical integration for supply chain resilience

Mallinckrodt Pharmaceuticals: Generic portfolio optimization

Market Ecosystem

Raw material suppliers — provide APIs, excipients, and packaging components for drug formulation

Contract development and manufacturing organizations (CDMOs) — produce clinical and commercial drug supplies

Biopharmaceutical companies — develop novel therapeutics through preclinical and clinical stages

Regulatory authorities — oversee clinical trial approvals and product licensing requirements

Health insurance providers — determine reimbursement coverage and formulary placement

Healthcare professionals — diagnose conditions and prescribe therapies to patients

Patient advocacy groups — raise awareness and support access to treatment options

Recent Industry Insights

Analyst Overview

Table of Contents